iVexSol is excited to support innovation in CGT with our new Packaging Cell Line Early Access Program. Here’s how it works, and how you can enroll today.
LEXINGTON, Mass., May 6, 2023 -- Fast, effective cell and gene therapy development requires a truly flexible approach to lentiviral vector. iVexSol is honored to offer further support to the CGT sector with our new Packaging Cell Line Early Access Program.
What is the iVexSol Packaging Cell Line?
Our Packaging Cell Line provides a quick-start LVV kit for early-stage CGTs.
What are the benefits of iVexSol’s Stable LVV technology?
What are the program criteria?
This Early Access program is open to companies in the IND-enabling stage or beyond, developing cell and gene therapies that utilize lentiviral vectors for gene delivery. All Genes oInterest (GOIs) are encouraged! Our platform is designed for flexibility and universal use.
Is there a screening process?
To ensure a successful program, iVexSol will conduct a brief screening process to assess your company's fit forthe program based on the following criteria:
Why should my organization consider enrolling?
Apply today
https://forms.office.com/r/m3QCEL348F
Once you submit this form, our team will review your application and contact you to discuss your eligibility for the program.
For more information, please contact Director of Business Development Kaytrina Anchelia at info@ivexsol.com.
Privacy Statement
We value your privacy. The information you provide will be used solely for the purposes of evaluating your company's fit for the Early Access Program and will not be shared with any third party.